N4 Pharma PLC - Placing and Subscription to raise £630,000

N4 Pharma Plc (AIM: N4P) has successfully raised £630,000 through a placing and subscription of new shares. The funds will be used to advance its primary work streams, including the development of a new treatment for irritable bowel disease (IBD) with the University of Queensland, supporting ongoing work with SRI International, and pursuing pre-IND approval for Nanogenics’ ECP105. Additionally, the company aims to expand its board with experienced directors in the pharmaceutical and biotech sectors.

Have Questions? Submit your questions directly to the management team here on our interactive investor hub.